CClinicalTrials.gg
CompletedNCT00286741Updated Jan 9, 2019Results posted

Can Group Visits Improve Outcomes of Veterans With Diabetes

A Phase 3 interventional study of Diabetes Group Management Visits in Diabetes and Hypertension, sponsored by US Department of Veterans Affairs. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by US Department of Veterans Affairs · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Sex
All
01

Study summary

Background: Diabetes is a common, morbid and expensive disease among veterans. Achieving adequate glycemic control and blood pressure control can reduce the devastating complications of diabetes. Because the majority of patients do not achieve adequate control of blood sugar and blood pressure, innovative strategies to improve control are needed. One strategy with great potential for veterans receiving VA care is the group clinic. Group clinics have been developed over the last 5-10 years, and have been shown to improve clinical outcomes and reduce outpatient utilization in geriatric settings. Group medical clinics involve a cohort of 8-20 patients who have 1-2 hour group visits. These clinics are distinguished from traditional group education visits for diabetes by the fact that these visits involve one physician and one or more additional health care professionals, usually a nurse practitioner and/or a pharmacist, and are designed to make management changes for a number of people with the same disease in a short period of time. The effect of group medical clinics on blood sugar, blood pressure, and the cost of diabetes care, is unknown. Objectives: Our primary objectives in this project are to determine the effectiveness and cost-effectiveness of a group visit intervention in improving rates of control of diabetes and high blood pressure in patients with both illnesses.

Read the detailed description

Background:

Diabetes is a common, morbid and expensive disease among veterans. Achieving adequate glycemic control and blood pressure control can reduce the devastating complications of diabetes. Because the majority of patients do not achieve adequate control of blood sugar and blood pressure, innovative strategies to improve control are needed. One strategy with great potential for veterans receiving VA care is the group clinic. Group clinics have been developed over the last 5-10 years, and have been shown to improve clinical outcomes and reduce outpatient utilization in geriatric settings. Group medical clinics involve a cohort of 8-20 patients who have 1-2 hour group visits. These clinics are distinguished from traditional group education visits for diabetes by the fact that these visits involve one physician and one or more additional health care professionals, usually a nurse practitioner and/or a pharmacist, and are designed to make management changes for a number of people with the same disease in a short period of time. The effect of group medical clinics on blood sugar, blood pressure, and the cost of diabetes care, is unknown.

Objectives:

Our primary objectives in this project were to determine the effectiveness and cost-effectiveness of a group visit intervention in improving rates of control of diabetes and high blood pressure in patients with both illnesses.

Methods:

We performed a two-site, randomized, controlled trial of group medical visits for diabetes management. Patients were patients in primary care at the Durham or Richmond VAMC's who had inadequate control of both their blood sugar and their blood pressure. We excluded patients with life-limiting illness. Patients randomized to the control arm received usual primary care. Patients randomized to the intervention arm were assigned to attend a group medical clinic every two months for one year. In the clinic, a primary care physician, with the assistance of a nurse and a pharmacist, measured blood pressure at the point of care, reviewed blood sugar logs, and then made all necessary medical changes for patients with diabetes. The primary outcomes were hemoglobin A1c and systolic blood pressure. Additional outcomes will be serum LDL-cholesterol, diabetes-specific quality of life, and health services utilization. Formative evaluation was undertaken to determine the mechanism of the intervention and to prepare for more successful dissemination if the intervention is effective. Formal cost analysis will be performed and cost-effectiveness analysis will be undertaken. All outcomes were measured at baseline, and 6 and 12 months after the beginning of the intervention.

Status:

All patient contact complete. Project is in analysis phase.

02

Conditions studied

  • Diabetes
  • Hypertension

Keywords

  • Diabetes
  • Hypertension
  • Randomized controlled trials
  • cost-effectiveness
  • health services
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 239 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

US Department of Veterans Affairs is the lead sponsor of 658 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Primary care at one of two participating sites,
  • HbA1c >= 7.5%, Systolic BP > 140 OR Diastolic BP > 90 on 2 consecutive measurements

Exclusion criteria

Exclusion Criteria:

-Primary care provider excludes patient from study, -Patient states that primary care is shared with non-VA primary care provider, -New enrollment in endocrine clinic within the last 6 months, -Patient is reluctant to participate in group visit for any reason, -Reduced life expectancy, as determined by any of the following: -New York Heart Association Class IV congestive heart failure, -Lung disease requiring supplemental oxygen, -End-stage renal disease on dialysis, -Current malignancy with any evidence of disease or currently undergoing chemotherapy or radiation therapy, -Cirrhosis of the liver, or -AIDS (HIV disease does not exclude a patient in the absence of an AIDS diagnosis), -Five or more errors on Short Portable Mental Status Questionnaire, Psychotic illness with hospitalization within three years prior to enrollment

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Medical group visits

    Medical group visits

    Other: Diabetes Group Management Visits

  • No intervention
    Treatment as Usual control

    control

Interventions

  • OtherDiabetes Group Management Visits

    Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1c

    Time frame: 12 months

  2. Systolic Blood Pressure

    Time frame: 12 months

Secondary outcomes

  1. Cost-effectiveness, Proportion of Patients With LDL < 100, Health Services Utilization, Quality of Life (as Measured by DQoL), Patient Empowerment (as Measured by DES).

    Time frame: one year

07

Results

Posted Sep 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneMedical Group VisitsControl
Started133106
Completed12289
Not completed1117

Outcome measures

PrimaryHemoglobin A1c
Time frame:
12 months
Reported as:
Mean · percentage points
Hemoglobin A1c
percentage pointsMedical Group VisitsControl
Hemoglobin A1c8.4 ± 1.38.7 ± 1.5
Statistical analysis
  • Medical Group Visits vs Control · Mixed Models Analysis · p = 0.15
PrimarySystolic Blood Pressure
Time frame:
12 months
Reported as:
Mean · mmHg
Systolic Blood Pressure
mmHgMedical Group VisitsTreatment as Usual Control
Systolic Blood Pressure140 ± 14.8147 ± 13.4
Statistical analysis
  • Medical Group Visits vs Treatment as Usual Control · Mixed Models Analysis · p = 0.03
SecondaryCost-effectiveness, Proportion of Patients With LDL < 100, Health Services Utilization, Quality of Life (as Measured by DQoL), Patient Empowerment (as Measured by DES).
Time frame:
one year

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Medical Group Visits—59/133 (44.4%)122/133 (91.7%)
Control—37/106 (34.9%)85/106 (80.2%)
Most frequent serious events
Most frequent serious events
EventMedical Group VisitsControl
All-Cause hospitalizationGeneral disorders56/13336/106
DeathGeneral disorders3/1331/106
Most frequent other events
Most frequent other events
EventMedical Group VisitsControl
HypoglycemiaEndocrine disorders101/13383/106
LightheadednessVascular disorders66/13362/106
Renal insufficiencyRenal and urinary disorders71/13351/106
HypotensionVascular disorders19/13314/106
Hepatic insufficiencyHepatobiliary disorders2/1332/106

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1Arm 2Total
Mean63 ± 9.460.8 ± 1062.0 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1Arm 2Total
Female6410
Male127102229
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1Arm 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7271143
White572986
More than one race000
Unknown or Not Reported4610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1Arm 2Total
Hispanic or Latino325
Not Hispanic or Latino128103231
Unknown or Not Reported213
08

Study locations

2 sites
  • Durham VA Medical Center, Durham, NC
    Durham, North Carolina 27705, United States
  • Hunter Holmes McGuire VA Medical Center, Richmond, VA
    Richmond, Virginia 23249, United States
09

References and documents

Publications

  • Edelman D, Fredrickson SK, Melnyk SD, Coffman CJ, Jeffreys AS, Datta S, Jackson GL, Harris AC, Hamilton NS, Stewart H, Stein J, Weinberger M. Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial. Ann Intern Med. 2010 Jun 1;152(11):689-96. doi: 10.7326/0003-4819-152-11-201006010-00001. PubMed 20513826 ↗
  • Crowley MJ, Melnyk SD, Ostroff JL, Fredrickson SK, Jeffreys AS, Coffman CJ, Edelman D. Can group medical clinics improve lipid management in diabetes? Am J Med. 2014 Feb;127(2):145-51. doi: 10.1016/j.amjmed.2013.09.027. Epub 2013 Oct 15. PubMed 24462012 ↗
  • Jackson GL, Edelman D, Olsen MK, Smith VA, Maciejewski ML. Benefits of participation in diabetes group visits after trial completion. JAMA Intern Med. 2013 Apr 8;173(7):590-2. doi: 10.1001/jamainternmed.2013.2803. No abstract available. PubMed 23478796 ↗
  • Crowley MJ, Melnyk SD, Coffman CJ, Jeffreys AS, Edelman D. Impact of baseline insulin regimen on glycemic response to a group medical clinic intervention. Diabetes Care. 2013 Jul;36(7):1954-60. doi: 10.2337/dc12-1905. Epub 2013 Feb 7. PubMed 23393214 ↗
  • Edelman D, Dolor RJ, Coffman CJ, Pereira KC, Granger BB, Lindquist JH, Neary AM, Harris AJ, Bosworth HB. Nurse-led behavioral management of diabetes and hypertension in community practices: a randomized trial. J Gen Intern Med. 2015 May;30(5):626-33. doi: 10.1007/s11606-014-3154-9. Epub 2015 Jan 8. PubMed 25567758 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00286741
Lead sponsor
US Department of Veterans Affairs
Responsible party
Sponsor
First posted
Feb 3, 2006
Start date
Jun 2006
Primary completion
Sep 2008
Completion
Jan 2009
Results posted
Sep 11, 2014
Last update
Jan 9, 2019

Study contacts

David Edelman, MD MHS
principal investigator · Durham VA Medical Center, Durham, NC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion